Sanofi Recalls Elitek (Rasburicase) Vials Due to Stability Testing Failures
Sanofi-Aventis is recalling 7,451 vials of Elitek (rasburicase) because routine stability testing showed enzyme activity levels were out of specification.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: The recall is classified as FDA Class II, and the source text does not report any illnesses or injuries, fitting the criteria for a moderate severity recall involving potential quality issues without immediate harm.
Plain-English summary
Sanofi-Aventis U.S. LLC is recalling 7,451 vials of Elitek (rasburicase) for injection, 7.5 mg. The recall involves Lot A9306, which has an expiration date of 2/28/2022. The product is distributed nationwide in the US.
The recall was initiated because routine stability testing revealed out-of-specification results for enzyme activity levels. This indicates that the product may not meet its required stability specifications.
Healthcare providers and patients should stop using the affected vials and contact Sanofi-Aventis for further instructions or to arrange for return of the product.
The recalled product
- Product
- ELITEK (RASBURICASE)
- Brand
- ELITEK
- Manufacturer
- Sanofi-Aventis U.S. LLC
- Category
- Drug — Prescription Injection
- Affected units
- 7,451
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot #: A9306
- Exp 2/28/2022
Distribution
Distributed nationwide across the United States.
Related recalls
Same manufacturer · Sanofi-Aventis U.S. LLC
See all →- HighADMELOG Insulin Lispro Recalled for Malformed Seal Defect
FDA (Drugs) · 2023-05-24
- SevereSanofi Recalls Zantac Tablets Due to NDMA Impurity
FDA (Drugs) · 2019-12-11
- SevereSanofi Recalls Zantac 150 mg Tablets Due to NDMA Impurity
FDA (Drugs) · 2019-12-11
- SevereSanofi Recalls Regular Strength Zantac 75 mg Due to NDMA Impurity
FDA (Drugs) · 2019-12-11
- SevereSanofi Recalls Zantac 150 mg Tablets Due to NDMA Impurity
FDA (Drugs) · 2019-12-11
Same hazard · stability failure
See all →- ModerateApotex Recalls Paxil Tablets for Failed Dissolution and Stability Testing
FDA (Drugs) · 2026-09-02
- ModerateVasocaine lidocaine spray recalled because stability data does not support expiry
FDA (Drugs) · 2026-03-11
- ModerateZone 1 lidocaine cream recalled because stability data does not support expiry
FDA (Drugs) · 2026-03-11
- ModerateZone 2 lidocaine cream recalled because stability data does not support expiry
FDA (Drugs) · 2026-03-11
- ModerateCiclopirox shampoo recalled after failing impurity specifications at eighteen months
FDA (Drugs) · 2025-12-24